21 November 2024 : Clinical Research
Decreased RSPO3 and β-Catenin in Preeclampsia: Correlation with Blood Pressure and Pregnancy Outcomes
Yunyun Liu1ABCDEF, Peishan Li1BCEF, Juan Liao1CD, Mingli Rao1BC, Ling Peng1C, Hua Gan1C, Lin Shang1C, Zhenghua Xiao1AG*, Xue Liu1AGDOI: 10.12659/MSM.945848
Med Sci Monit 2024; 30:e945848
Table 2 Clinical characteristics of control group and preeclampsia group.
| Control (n=60) | Preeclampsia (n=60) | P value | |
|---|---|---|---|
| Age (years) | 30.00 (28.00, 33.00) | 30.00 (28.00, 34.00) | 0.881 |
| Maximum systolic blood pressure (mmHg) | 119.78±9.37 | 156.20±15.51 | <0.001 |
| Maximum diastolic blood pressure (mmHg) | 75.43±7.27 | 97.52±12.85 | <0.001 |
| Gestational age at delivery (weeks) | 39.10 (38.55, 39.57) | 37.30 (35.03, 38.50) | <0.001 |
| Pre-BMI (kg/m) | 22.81±2.85 | 27.63±5.16 | <0.001 |
| BMI at delivery (kg/m) | 27.89±3.35 | 26.92±4.65 | 0.192 |
| Weight gain (kg) | 13.97±4.15 | 13.61±6.20 | 0.713 |
| Uric acid (umol/L) | 313.98±59.05 | 423.55±127.40 | <0.001 |
| Creatinine (umol/L) | 44.00 (39.00, 48.75) | 51.50 (44.25, 60.75) | <0.001 |
| Hemoglobin (g/L) | 127.00 (117.50, 132.00) | 125.50 (113.50, 133.50) | 0.534 |
| Platelets (10/L) | 189.33±50.01 | 188.58±71.06 | 0.947 |
| Total bile acids (umol/L) | 2.75 (1.63, 5.08) | 5.20 (2.30, 7.20) | 0.001 |
| Non-bound bile acids (ug/L) | 4.10 (1.90, 5.90) | 3.75 (2.05, 5.25) | 0.719 |
| Albumin (g/L) | 36.57±2.61 | 33.29±4.92 | <0.001 |
| Aspartate aminotransferase (U/L) | 22.00 (19.25, 25.00) | 22.00 (19.00, 29.00) | 0.304 |
| Alanine transaminase (U/L) | 16.00 (13.00, 21.75) | 19.00 (14.25, 26.75) | 0.031 |
| S/D | 2.12 (1.95, 2.34) | 2.46 (2.14, 2.70) | <0.001 |
| RI | 0.53 (0.49, 0.58) | 0.59 (0.54, 0.66) | <0.001 |
| Data that conform to normally distributed measurements are expressed as mean (±standard deviation); data that do not conform to the normally distributed measurements are expressed as quartiles. The test and Kruskal-Wallis test were used for 2-group pairwise comparisons. Significant at | |||